SUPPORTING STATEMENT
Requirements for Collection of Data Relating to the Prevention of Medical Gas Mix-ups at Health Care Facilities
Survey
OMB Control Number 0910-0548
A. Justification
1. Circumstances of Information Collection
The Food and Drug Administration (FDA) plans to conduct a survey to determine the rate of compliance with its recommendations pertaining to Health Care Facilities and to determine the success rate at preventing medical gas mix-ups from occurring. FDA received reports of medical gas mix-ups occurring during the past 9 years. These reports involved hospitals and nursing home facilities and involved 7 deaths and 15 injuries to patients who were thought to be receiving medical grade oxygen, but instead were actually receiving a different gas that had been mistakenly connected to the facility’s oxygen supply system.
2. Purpose and Use of Information
To assess the effectiveness of implementing FDA’s recommendations on the prevention of medical gas mix-ups at hospitals, nursing homes, and health care facilities. Implementing all of the recommendations will result in increased protection of the public health by assuring that the employees of hospitals, nursing homes and health care facilities receive adequate training in understanding the hazardous associated with handling medical gases. This should provide a higher degree of certainty that only medical grade oxygen is connected to an oxygen supply system.
3. Use of Improved Information Technology
Even though advanced technologies for the gathering and reporting of data possibly do exist, investigators collect this information during their usual and customary investigators workday.
4. Efforts to Identify Duplication
This assignment is unique in that there are no regulatory requirements for health care facilities. However, hospitals, nursing homes, and health care facilities were requested to voluntarily implement our recommendations that will greatly enhance the degree of safety associated with connecting medical grade oxygen to their oxygen supply system.
5. Involvement of Small Entities
FDA investigators will visit a representative number of health care facilities and speak to the managers responsible for the handling of medical gases. The managers will be asked to provide answers to several assignment questions. So under the Regulatory Flexibility Act, there will only minimal impact on small entities.
6. Consequences If Information Collected Less Frequently
This is a one-time survey.
7. Consistency with the Guidelines in 5 CFR 1320.5(d)(2)
There is no inconsistency resulting from this survey.
8. Consultation Outside the Agency
As required under section 3506 (c)(2)(B) of the Paperwork Reduction Act, FDA provided an opportunity for public comment on January 3, 2006 (71 FR 122). No comments were received on the information collection estimates.
9. Remuneration of Respondents
FDA has not provided and has no intention to provide any payment or gift to respondents under this guidance.
10. Assurance of Confidentiality
Confidentiality of information is protected under 21 CFR 314.430, 21 CFR 601, and 21 CFR part 20.
11. Questions of a Sensitive Nature
There are no questions of a sensitive nature.
Estimates of Annualized Hour Burden
21 CFR Section |
No. of Respondents |
Annual Frequency per Response |
Total Annual Responses |
Hours per Response |
Total Hours |
210/211 |
285 |
1 |
285 |
.25 |
71.25 |
|
|
|
|
|
|
Total |
285 |
1 |
285 |
.25 |
71.25 |
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
13. Estimates of Annualized Cost Burden to Respondents
FDA has estimated that the cost to health care facilities would be minimal, and would only involve the time it takes for management to provide a response to each question.
14. Estimates of Annualized Cost Burden to the Government
The investigators will include a visit to the assigned health care facilities on their normal inspectional coverage of drug firms. The Agency estimates that it will take 1 hour total to cover the assignment.
15. Changes In Burden
There is no change in the burden.
16. Time Schedule, Publication, and Analysis Plans
There are no publications.
17. Displaying of OMB Expiration Date
The agency is not seeking to display the expiration date for OMB approval of the information collection.
18. Exception to the Certification Statement - Item 19
There are no exceptions to the certification statement identified in Item 19, "Certification for Paperwork Reduction Act Submission," of OMB Form 83-I.
File Type | application/msword |
File Title | SUMMARY: The Food and Drug Administration (FDA) is amending its regulations governing the format in which certain labeling is r |
Author | CDER USER |
Last Modified By | eberbako |
File Modified | 2008-07-02 |
File Created | 2008-07-02 |